Squarepoint Ops LLC Avadel Pharmaceuticals PLC Transaction History

Squarepoint Ops LLC

  • $62.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$6.49 - $9.91 $182,771 - $279,085
-28,162 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$6.73 - $9.05 $108,985 - $146,555
16,194 Added 135.31%
28,162 $190,000
Q1 2021

May 17, 2021
SELL
$6.61 - $10.07 $295,453 - $450,108
-44,698 Reduced 78.88%
11,968 $108,000
Q4 2020

Feb 16, 2021
SELL
$5.03 - $7.95 $22,629 - $35,767
-4,499 Reduced 7.36%
56,666 $379,000
Q3 2020

Nov 16, 2020
BUY
$5.02 - $8.98 $307,048 - $549,261
61,165 New
61,165 $308,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email